A detailed history of Pro Share Advisors LLC transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 15,466 shares of AVIR stock, worth $53,512. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,466
Previous 19,671 21.38%
Holding current value
$53,512
Previous $79,000 35.44%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$3.31 - $4.04 $13,918 - $16,988
-4,205 Reduced 21.38%
15,466 $51,000
Q1 2024

May 08, 2024

BUY
$3.09 - $4.56 $5,101 - $7,528
1,651 Added 9.16%
19,671 $79,000
Q4 2023

Feb 14, 2024

BUY
$2.8 - $3.35 $7,305 - $8,740
2,609 Added 16.93%
18,020 $54,000
Q3 2023

Nov 13, 2023

BUY
$3.0 - $3.79 $135 - $170
45 Added 0.29%
15,411 $46,000
Q2 2023

Aug 10, 2023

BUY
$3.21 - $5.06 $1,948 - $3,071
607 Added 4.11%
15,366 $57,000
Q1 2023

May 11, 2023

SELL
$3.0 - $4.97 $5,844 - $9,681
-1,948 Reduced 11.66%
14,759 $49,000
Q4 2022

Feb 02, 2023

BUY
$4.35 - $6.17 $5,615 - $7,965
1,291 Added 8.37%
16,707 $80,000
Q3 2022

Nov 04, 2022

BUY
$5.49 - $8.79 $1,981 - $3,173
361 Added 2.4%
15,416 $88,000
Q2 2022

Aug 01, 2022

SELL
$5.33 - $8.18 $30,199 - $46,347
-5,666 Reduced 27.34%
15,055 $108,000
Q1 2022

May 10, 2022

SELL
$5.5 - $9.19 $28,072 - $46,905
-5,104 Reduced 19.76%
20,721 $150,000
Q4 2021

Feb 08, 2022

BUY
$7.67 - $44.59 $134,616 - $782,599
17,551 Added 212.12%
25,825 $231,000
Q3 2021

Nov 12, 2021

SELL
$21.33 - $35.06 $190,455 - $313,050
-8,929 Reduced 51.9%
8,274 $290,000
Q2 2021

Aug 13, 2021

BUY
$19.22 - $59.08 $251,724 - $773,770
13,097 Added 318.97%
17,203 $370,000
Q1 2021

May 14, 2021

BUY
$41.42 - $88.44 $170,070 - $363,134
4,106 New
4,106 $254,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $288M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.